• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    5/9/23 1:31:31 PM ET
    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BLCM alert in real time by email

    Gainers

    • TScan Therapeutics (NASDAQ:TCRX) stock rose 122.3% to $5.0 during Tuesday's regular session. The current volume of 41.6 million shares is 104202.1% of TScan Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $123.1 million.
    • Novavax (NASDAQ:NVAX) stock rose 37.04% to $10.21. The current volume of 33.2 million shares is 585.1% of Novavax's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $879.8 million. The company's, Q1 earnings came out today.
    • Voyager Therapeutics (NASDAQ:VYGR) stock moved upwards by 34.11% to $11.14. The current volume of 2.5 million shares is 845.4% of Voyager Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $484.9 million. As per the press release, Q1 earnings came out today.
    • Ensysce Biosciences (NASDAQ:ENSC) stock increased by 32.99% to $4.58. As of 13:30 EST, Ensysce Biosciences's stock is trading at a volume of 24.8 million, which is 13244.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.8 million.
    • Venus Concept (NASDAQ:VERO) stock moved upwards by 31.38% to $0.24. Trading volume for Venus Concept's stock is 3.5 million as of 13:30 EST. This is 1299.5% of its average full-day volume over the last 100 days. The company's market cap stands at $19.4 million.
    • Longeveron (NASDAQ:LGVN) stock moved upwards by 28.16% to $4.05. As of 13:30 EST, Longeveron's stock is trading at a volume of 5.3 million, which is 24941.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $85.2 million.

    Losers

    • Trevena (NASDAQ:TRVN) stock declined by 38.9% to $1.9 during Tuesday's regular session. Trevena's stock is trading at a volume of 18.9 million shares as of 13:30 EST. This is 1002.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.2 million.
    • Lexaria Bioscience (NASDAQ:LEXX) stock decreased by 26.95% to $0.75. As of 13:30 EST, Lexaria Bioscience's stock is trading at a volume of 1.0 million, which is 3758.6% of its average full-day volume over the last 100 days. The company's market cap stands at $4.4 million.
    • Enanta Pharma (NASDAQ:ENTA) stock fell 26.86% to $25.11. Trading volume for Enanta Pharma's stock is 607.3K as of 13:30 EST. This is 338.6% of its average full-day volume over the last 100 days. The company's market cap stands at $524.4 million. The company's, Q2 earnings came out yesterday.
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) stock fell 26.56% to $0.71. Bellicum Pharmaceuticals's stock is trading at a volume of 4.0 million shares as of 13:30 EST. This is 141.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.3 million.
    • Coherus BioSciences (NASDAQ:CHRS) shares declined by 26.48% to $5.99. Trading volume for Coherus BioSciences's stock is 3.5 million as of 13:30 EST. This is 346.8% of its average full-day volume over the last 100 days. The company's market cap stands at $482.0 million. As per the press release, Q1 earnings came out yesterday.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) stock decreased by 20.42% to $0.41. Trading volume for this security as of 13:30 EST is 2.4 million, which is 222.0% of its average full-day volume over the last 100 days. The company's market cap stands at $25.3 million. As per the press release, Q1 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BLCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCM
    $CHRS
    $ENSC
    $ENTA

    CompanyDatePrice TargetRatingAnalyst
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Enanta Pharmaceuticals Inc.
    $ENTA
    11/14/2025Overweight
    Analyst
    TScan Therapeutics Inc.
    $TCRX
    11/14/2025Overweight → Equal-Weight
    Morgan Stanley
    Novavax Inc.
    $NVAX
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    Enanta Pharmaceuticals Inc.
    $ENTA
    10/1/2025$20.00Hold → Buy
    Jefferies
    Coherus Oncology Inc.
    $CHRS
    9/4/2025Hold → Buy
    Maxim Group
    Novavax Inc.
    $NVAX
    8/28/2025$10.00Buy
    H.C. Wainwright
    Novavax Inc.
    $NVAX
    8/20/2025$7.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ

    3/19/26 10:00:00 AM ET
    $DAWN
    $ENGN
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    SEC Filings

    View All

    SEC Form PRE 14A filed by Tonix Pharmaceuticals Holding Corp.

    PRE 14A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/20/26 5:12:47 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/18/26 6:01:48 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Longeveron Inc.

    10-K - Longeveron Inc. (0001721484) (Filer)

    3/17/26 4:01:02 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tonix Pharmaceuticals Holding Corp.

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    3/18/26 5:03:27 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bunka Christopher

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    3/18/26 11:37:13 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Willard Stephen H was granted 400,000 shares and covered exercise/tax liability with 105,533 shares (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:59:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on Enanta Pharmaceuticals

    Analyst initiated coverage of Enanta Pharmaceuticals with a rating of Overweight

    11/14/25 11:26:32 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TScan Therapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded TScan Therapeutics from Overweight to Equal-Weight

    11/14/25 10:24:29 AM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $73,552 worth of shares (81,732 units at $0.90) and bought $71,974 worth of shares (80,069 units at $0.90) (SEC Form 4)

    4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

    12/23/25 6:17:28 PM ET
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Taylor Carolyn E. bought $15,061 worth of shares (418 units at $36.03) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/21/25 5:22:56 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Treco James bought $9,000 worth of shares (250 units at $36.00) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/20/25 4:15:15 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

    CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. Ms. Ishak will lead Tonix's legal, corporate governance, and compliance functions. "Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "Her deep background in complex transactions, public company matters, and governa

    12/9/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLCM
    $CHRS
    $ENSC
    $ENTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 6:13:11 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 5:12:26 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care